



2020 USCAP Companion Meeting

Sunday, March 1, 2020 – 8:30am-12:00 noon

Los Angeles Convention Center

Los Angeles, California, USA

Contemporary Role of Ultrastructure in Tumor Diagnosis: Potential Contribution to Targeted Therapy

The symposium will provide an overview of and highlight recent developments in the diagnosis of sarcomas and newly diagnosed renal tumors, emphasizing a multimodality and multidisciplinary approach. In the current practice of surgical pathology, the small tissue sample sizes received for diagnostic workup may be insufficient for all modalities. In this setting ultrastructural pathology should be viewed as an important tool to narrow a differential diagnosis, and its contribution may assist pathologists in making more accurate diagnoses of tumors, particularly crucial in the current era of targeted molecular and immune-based therapies. The symposium will touch on the potential role of electron microscopy in developing and monitoring targeted therapies at the cellular level.

Course Learning Objectives

Upon completion of this educational activity, the learner will be able to:

- Describe the different technical modalities used for diagnoses of selected tumors
- Describe the ultrastructural features and relevance thereof in narrowing a differential diagnosis of selected tumors
- Describe for selected cancers the multidisciplinary approach to therapy
- Discuss potential contributions of electron microscopy in targeted therapies

Presentations

Title	Presenters	
Introduction	Giovanna M. Crisi, MD, PhD Baystate Health Springfield, MA, USA	Giovanna M. Crisi, MD, PhD
Potential Impact of Electron Microscopy in Cancer Treatment	Josep Lloreta-Trull, MD, PhD Hospital del Mar, Parc de Salut Mar, Universitat Pompeu Fabra Barcelona, Spain	Josep Lloreta-Trull, MD, PhD
Genetic Targets in Sarcomas	Paola Dal Cin, PhD Brigham and Women's Hospital Boston, MA, USA	Paola Dal Cin, PhD

Is There a Role for Electron Microscopy in Soft Tissue Tumor Diagnosis

Cyril Fisher, MD, DSc
University Hospitals Birmingham,
NHS Foundation Trust
Birmingham, UK

**Cyril
Fisher,
MD, DSc**

Contribution of Electron Microscopy to the Diagnosis of the New Subtypes of Renal Tumors

Maria J. Merino, MD
, National Cancer Institute
Bethesda, MD, USA

**Maria J.
Merino,
MD**

Renal Tumors: A Model of the Joint Venture of Oncology and Pathology

Joaquim Bellmunt, MD
, Beth Israel Deaconess Medical
Center, Harvard Medical School
Boston, MA, USA

**Joaquim
Bellmun
t, MD**

Moderators

**Giovanna M. Crisi,
MD, PhD**
Baystate Health
Springfield, MA, USA

**Giovann
a Crisi,
MD, PhD**

Josep Lloreta-Trull, MD, PhD
Hospital del Mar, Parc de Salut Mar,
Universitat Pompeu Fabra
Barcelona, Spain

**Josep
Lloreta-
Trull,
MD, PhD**

Continuing Medical Education and Continuing Certification

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The United States and Canadian Academy of Pathology and Society for Ultrastructural Pathology. The United States and Canadian Academy of Pathology is accredited by the ACCME to provide continuing medical education for physicians.

The United States and Canadian Academy of Pathology designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

USCAP is approved by the American Board of Pathology (ABPath) to offer Self-Assessment credits (SAMs) and Lifelong Learning (Part II) credit for the purpose of meeting the ABPath requirements for Continuing Certification (CC).

Physicians can earn a maximum of 3 SAM/Part II credit hours.
